Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

A Study of E7389 in Advanced/Metastatic Breast Cancer Patients

3. April 2013 aktualisiert von: Eisai Inc.

A Phase II Open Label Study of E7389 (Halichondrin B Analog) in Patients With Advanced/Metastatic Breast Cancer Previously Treated With Chemotherapy Including An Anthracycline and A Taxane

The purpose of this study is to determine if E7389 is a safe and effective treatment for advanced/metastatic breast cancer.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

The primary objective is to determine the response rate (RR) to E7389 monotherapy administered as an IV bolus of 1.4 mg/m^2 on Days 1, 8, and 15 of a 28-Day cycle and on Days 1 and 8 of a 21-day cycle in patients with advanced/metastatic breast cancer treated with chemotherapy including an anthracycline and a taxane, with previously documented progression during or within six months following the last dose of prior chemotherapy.

The secondary objectives are to evaluate:

  • The safety and tolerability of E7389 monotherapy in this patient population;
  • The antitumor activity of E7389 as determined by duration of response, time to progression, and overall survival;
  • Quality of life measured by the Functional Assessment of Cancer Therapy-Breast (FACT-B) questionnaire/tumor-related symptom improvement or worsening measured by pain intensity on a visual analog scale (VAS), analgesics consumption, weight changes and performance status (PS);
  • Tumor pharmacogenetics and their possible relationship to response (assessment of beta-tubulin isotype mRNA on biopsy sample) in patients who have signed a separate consent form

Studientyp

Interventionell

Einschreibung (Tatsächlich)

104

Phase

  • Phase 2

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Arkansas
      • Jonesboro, Arkansas, Vereinigte Staaten
    • California
      • Deer Park, California, Vereinigte Staaten
      • La Verne, California, Vereinigte Staaten
      • Pasadena, California, Vereinigte Staaten
      • Pomona, California, Vereinigte Staaten
    • Florida
      • Brooksville, Florida, Vereinigte Staaten
      • New Port Richey, Florida, Vereinigte Staaten
      • Plantation, Florida, Vereinigte Staaten
    • Louisiana
      • New Orleans, Louisiana, Vereinigte Staaten
    • Mississippi
      • Southaven, Mississippi, Vereinigte Staaten
    • Montana
      • Missoula, Montana, Vereinigte Staaten
    • New York
      • Syracuse, New York, Vereinigte Staaten
    • Ohio
      • Middletown, Ohio, Vereinigte Staaten
    • Tennessee
      • Memphis, Tennessee, Vereinigte Staaten
    • Texas
      • Amarillo, Texas, Vereinigte Staaten
      • Richardson, Texas, Vereinigte Staaten

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Weiblich

Beschreibung

Inclusion Criteria:

  • Female patients with histologically or cytologically confirmed carcinoma of the breast
  • Patients with advanced/metastatic disease that is not amenable to curative therapy (either surgery or radiation therapy)
  • Patients must have measurable disease by the RECIST criteria, defined as at least one lesion that can be accurately measured in at least one diameter (at least 10 mm in longest diameter (LD) by spiral computer tomography (CT) scan, or at least 20 mm by standard techniques; If the only measurable lesion is a lymph node, it must measure at least 20 mm in LD. If a single lesion is identified as the target lesion, a cytological or histological confirmation of breast carcinoma is required.
  • Patients must have had prior treatment with an anthracycline and a taxane (either sequential or in combination) and may have had prior treatment with other agents as well.
  • Patients must have progressed within six months of the last dose of chemotherapy, or experienced disease progression while receiving chemotherapy for advanced/metastatic disease.
  • Resolution of all chemotherapy or radiation-related toxicities to less than grade 1 severity
  • Age ≥ 18 years
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (APPENDIX 4) of 0 or 1
  • Life expectancy of ≥ 3 months
  • Adequate renal function as evidenced by serum creatinine ≤ 1.5 mg/dL or calculated creatinine clearance ≥ 50 mL/minute (min) per the Cockcroft and Gault formula
  • Adequate bone marrow function as evidenced by absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L, hemoglobin ≥ 10.0 g/dL (a hemoglobin <10.0 g/dL would be acceptable if it can be corrected by growth factor or transfusion), and platelet count ≥ 100 x 10^9/L
  • Adequate liver function as evidenced by bilirubin ≤ 1.5 mg/dL and alkaline phosphatase, alanine transaminase (ALT), and aspartate transaminase (AST) ≤ 3 times the upper limits of normal (ULN) (in the case of liver metastases ≤ 5 x ULN)
  • Patients willing and able to complete the FACT-B questionnaire, Analgesic Diary, Pain VAS, and the tumor-related symptomatic assessment
  • Patients willing and able to comply with the study protocol for the duration of the study
  • A sample from the diagnostic biopsy (paraffin block) must be available
  • Written informed consent prior to any study-specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice

Exclusion Criteria:

  • Patients who have received chemotherapy, radiation, hormonal therapy, or Herceptin within 2 weeks of E7389 treatment start
  • Radiation therapy encompassing > 10% of marrow
  • Failure to recover from any chemotherapy related or other therapy related toxicity at study entry that is deemed to be clinically significant by the study investigator
  • Prior treatment with Mitomycin C or nitrosoureas
  • Prior high dose chemotherapy with hematopoietic stem cell rescue in the past two years
  • Pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring active treatment, including the use of oxygen
  • Active symptomatic brain metastasis; Patients with central Nervous System (CNS) metastasis are considered eligible if they have completed local therapy and discontinued from corticosteroids for at least two weeks before starting treatment with E7389
  • Patients with meningeal carcinomatosis
  • Patients who require therapeutic anti-coagulant therapy with Warfarin or related compounds; Mini dose warfarin for catheter related thrombosis prophylaxis is permitted
  • Women who are pregnant or breast-feeding; Women of childbearing potential with either a positive pregnancy test at Screening or no pregnancy test. Women of childbearing potential unless (1) surgically sterile or (2) using adequate measures of contraception in the opinion of the Investigator. Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.
  • Severe /uncontrolled intercurrent illness/infection
  • Significant cardiovascular impairment (history of congestive heart failure > NYHA grade II, unstable angina or myocardial infarction within the past six months, or serious cardiac arrhythmia)
  • Patients with organ allografts
  • Patients with known positive HIV status
  • Patients who have had a prior malignancy, other than carcinoma in situ of the cervix, or non-melanoma skin cancer, unless the prior malignancy was diagnosed and definitively treated ≥ 5 years previously with no subsequent evidence of recurrence
  • Patients with pre-existing neuropathy > Grade 1
  • Patients with a hypersensitivity to halichondrin B and/or halichondrin B chemical derivative
  • Patients who participated in a prior E7389 clinical trial
  • Patients with other significant disease or disorders that, in the Investigator's opinion, would exclude the patient from the study

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: E7389
The first cohort of subjects were to receive E7389 1.4 mg/m^2 as an intravenous (IV) bolus on Days 1, 8, and 15 of a 28-day cycle. A second cohort of subjects was added and were to receive E7389 1.4 mg/m^2 as an IV bolus on Days 1 and 8 of a 21-day cycle.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Overall Response Rate Based on Response Evaluation Criteria in Solid Tumors (RECIST)
Zeitfenster: Confirmed 4 to 8 weeks after first observed
Defined as the percentage of subjects with CR or PR from the start of treatment until disease progression or recurrence. Lesions measured by computed tomography (CT) scan and magnetic resonance imaging (MRI). Objective response rate: complete response (CR-disappearance of all lesions)+ partial response (PR-30% decrease in lesion diameter), Progressive Disease (PD-20% increase in lesion diameter), stable disease (SD-neither shrinkage nor increase of lesions).
Confirmed 4 to 8 weeks after first observed

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Duration of Response
Zeitfenster: From CR or partial response PR (whichever recorded first) to date of recurrent or progressive disease
Measured from the time measurement criteria were met for complete response (CR) or partial response (PR) (whichever was first recorded) until the first date that recurrent progressive disease was objectively documented (taking as a reference for progressive disease the smallest measurements recorded since the treatment started).
From CR or partial response PR (whichever recorded first) to date of recurrent or progressive disease
Progression Free Survival
Zeitfenster: From start of study drug administration to progressive disease or death
Defined as the time from start of study drug administration until progressive disease or death from any cause during the study period in the absence of disease progression.
From start of study drug administration to progressive disease or death
Overall Survival
Zeitfenster: From start of study drug administration to death
Defined as the time from the start of study drug administration until death from any cause
From start of study drug administration to death
Change From Baseline to Study Termination in Quality of Life Measures Using Functional Assessment of Cancer Therapy-Breast (FACT-B) Scores
Zeitfenster: At Screening, Day 1 of each cycle, and 30 days after last dose of study drug
The FACT-B questionnaire consists of 36 questions each scored from 0-4. The total score is calculated by summing these scores. The total possible range is from 0 to 144. The higher scores indicate a better health-related quality of life. This measures emotional, functional, physical, and social well being as well as concerns specific to patients with breast cancer.
At Screening, Day 1 of each cycle, and 30 days after last dose of study drug

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Nützliche Links

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn

1. September 2004

Primärer Abschluss (Tatsächlich)

1. November 2006

Studienabschluss (Tatsächlich)

1. November 2006

Studienanmeldedaten

Zuerst eingereicht

29. November 2004

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

29. November 2004

Zuerst gepostet (Schätzen)

30. November 2004

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Schätzen)

22. April 2013

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

3. April 2013

Zuletzt verifiziert

1. April 2013

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • E7389-A001-201

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Neoplasien der Brust

Klinische Studien zur E7389

3
Abonnieren